Abstract
Evaluation of: Liao H, Bonsignori M, Alam M et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186 (2013). In 2009, results from the Phase III HIV-1 vaccine clinical trial RV144 applying a prime/boost regimen with a canarypox vaccine vector ALVAC-HIV plus the AIDSVAX B/E subunit envelope vaccine conducted in Thailand were reported. The priming canarypox vector carried the HIV-1 vaccine genes gp120 linked to the transmembrane-anchoring portion of subtype B gp41, HIV-1 Gag and protease; the boosting vaccine was composed of clades B and E of HIV-1 gp120. A 31.2% vaccine efficacy could be seen in this trial, an encouraging result in HIV-1 vaccine research that had been previously plagued with little clinical efficacy. In this paper, results from tests of four monoclonal antibodies isolated from RV144 vaccinees are reported. The antibodies recognize a certain HIV-1 envelope residue (169), neutralize laboratory-adapted HIV-1 strains and mediate killing of CD4+ cells infected with HIV-1 laboratory isolates. Crystal structure analysis suggests that the recognized HIV-1 envelope epitope can exist in different conformations. It is thought that the immune pressure elicited by the monoclonal antibodies targets a HIV-1 envelope region with variable sequence structure.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 453-455 |
| Number of pages | 3 |
| Journal | Immunotherapy |
| Volume | 5 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2013 |
Fingerprint
Keywords
- antibodies against variable region of HIV-1
- broadly neutralizing antibodies
- CH58 and CH59 antibodies
- gp120 antibodies
- HIV-1 vaccine
- protective immunity
- RV144 clinical trial
ASJC Scopus subject areas
- Immunology and Allergy
- Oncology
- Immunology
Cite this
HIV-1 vaccine antibody induction against a variable region of HIV-1 : A possible link to protective immunity? / Bauer, Gerhard.
In: Immunotherapy, Vol. 5, No. 5, 05.2013, p. 453-455.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - HIV-1 vaccine antibody induction against a variable region of HIV-1
T2 - A possible link to protective immunity?
AU - Bauer, Gerhard
PY - 2013/5
Y1 - 2013/5
N2 - Evaluation of: Liao H, Bonsignori M, Alam M et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186 (2013). In 2009, results from the Phase III HIV-1 vaccine clinical trial RV144 applying a prime/boost regimen with a canarypox vaccine vector ALVAC-HIV plus the AIDSVAX B/E subunit envelope vaccine conducted in Thailand were reported. The priming canarypox vector carried the HIV-1 vaccine genes gp120 linked to the transmembrane-anchoring portion of subtype B gp41, HIV-1 Gag and protease; the boosting vaccine was composed of clades B and E of HIV-1 gp120. A 31.2% vaccine efficacy could be seen in this trial, an encouraging result in HIV-1 vaccine research that had been previously plagued with little clinical efficacy. In this paper, results from tests of four monoclonal antibodies isolated from RV144 vaccinees are reported. The antibodies recognize a certain HIV-1 envelope residue (169), neutralize laboratory-adapted HIV-1 strains and mediate killing of CD4+ cells infected with HIV-1 laboratory isolates. Crystal structure analysis suggests that the recognized HIV-1 envelope epitope can exist in different conformations. It is thought that the immune pressure elicited by the monoclonal antibodies targets a HIV-1 envelope region with variable sequence structure.
AB - Evaluation of: Liao H, Bonsignori M, Alam M et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186 (2013). In 2009, results from the Phase III HIV-1 vaccine clinical trial RV144 applying a prime/boost regimen with a canarypox vaccine vector ALVAC-HIV plus the AIDSVAX B/E subunit envelope vaccine conducted in Thailand were reported. The priming canarypox vector carried the HIV-1 vaccine genes gp120 linked to the transmembrane-anchoring portion of subtype B gp41, HIV-1 Gag and protease; the boosting vaccine was composed of clades B and E of HIV-1 gp120. A 31.2% vaccine efficacy could be seen in this trial, an encouraging result in HIV-1 vaccine research that had been previously plagued with little clinical efficacy. In this paper, results from tests of four monoclonal antibodies isolated from RV144 vaccinees are reported. The antibodies recognize a certain HIV-1 envelope residue (169), neutralize laboratory-adapted HIV-1 strains and mediate killing of CD4+ cells infected with HIV-1 laboratory isolates. Crystal structure analysis suggests that the recognized HIV-1 envelope epitope can exist in different conformations. It is thought that the immune pressure elicited by the monoclonal antibodies targets a HIV-1 envelope region with variable sequence structure.
KW - antibodies against variable region of HIV-1
KW - broadly neutralizing antibodies
KW - CH58 and CH59 antibodies
KW - gp120 antibodies
KW - HIV-1 vaccine
KW - protective immunity
KW - RV144 clinical trial
UR - http://www.scopus.com/inward/record.url?scp=84877246287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877246287&partnerID=8YFLogxK
U2 - 10.2217/imt.13.32
DO - 10.2217/imt.13.32
M3 - Article
C2 - 23638741
AN - SCOPUS:84877246287
VL - 5
SP - 453
EP - 455
JO - Immunotherapy
JF - Immunotherapy
SN - 1750-743X
IS - 5
ER -